CLSA Maintains WUXI BIO as Leading Industry Choice; Anticipates Strong NP Growth in 2H25
Positive Profit Alert: WUXI BIO has issued a positive profit alert for the second half of 2025, projecting a 17% year-on-year revenue growth and significant increases in net profit and adjusted net profit, exceeding market expectations.
Gross Profit Margin Growth: CLSA highlighted a notable expected increase in WUXI BIO's gross profit margin by 6.2 percentage points to 48.8%, which is a key factor in the company's better-than-expected earnings performance.
Analyst Ratings: CLSA continues to favor WUXI BIO as a top pick in China's Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors, maintaining a target price of HKD48.5 and an Outperform rating.
Market Context: The stock has experienced short selling of $127.94 million, with a ratio of 17.139%, indicating some market skepticism despite the positive outlook from CLSA.
Trade with 70% Backtested Accuracy
Analyst Views on 02269
About the author
CANBRIDGE-B Rises Over 5% Following Announcement of 14.7% Discounted Share Placement to WUXI BIO Subsidiary
Share Placement Announcement: CANBRIDGE-B (01228.HK) has announced the placement of 84.0336 million shares, representing approximately 14.12% of its enlarged share capital, to WuXi Biologics HealthCare Venture at a price of HKD2.38 per share, which is a 14.7% discount to the previous closing price.
Fundraising Details: The total amount raised from this share placement is expected to be HKD200 million, with net proceeds estimated at around HKD199 million.
JPM Increases WUXI BIO (02269.HK) Price Target to $51 Following Positive Profit Alert and Robust Order Growth
WUXI BIO Financial Performance: WUXI BIO's pre-announced 2025 results exceeded market expectations, with projected full-year revenue of RMB21.8 billion, a 16.7% increase YoY, and a net profit of RMB4.9 billion, surpassing both market consensus and JPMorgan's forecasts.
JPMorgan's Revised Forecasts: JPMorgan raised its sales forecasts for WUXI BIO by 2-5% for 2025-2027 and 6-9% for 2028 and beyond, anticipating sales growth of 17.3% in 2026 and 18.0% in 2027.
Target Price Adjustment: Following the positive outlook, JPMorgan increased its target price for WUXI BIO from $37 to $51 and extended the target price deadline to December 2026, maintaining an Overweight rating.
Market Activity: WUXI BIO's stock experienced a decline of 3.096%, with significant short selling activity amounting to $316.79 million and a short selling ratio of 10.140%.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
HKD1.4 Billion Net Inflow from Southbound Trading into TENCENT
Southbound Trading Inflows: TENCENT (00700.HK) saw a significant net inflow of HKD1.4 billion, while MEITUAN-W (03690.HK) also had a notable inflow of HKD314.6 million in Southbound Trading.
Southbound Trading Outflows: POP MART (09992.HK) experienced a net outflow of HKD301.1 million, with ZIJIN MINING (02899.HK) and WUXI BIO (02269.HK) also recording substantial outflows.
Short Selling Activity: TENCENT had short selling of $1.61 billion with a ratio of 7.556%, while MEITUAN-W faced $1.88 billion in short selling at a ratio of 24.332%.
Market Overview: Overall, Southbound Trading net outflow totaled HKD0, accounting for 39.70% of the total transaction amount of HKD94.78 billion.
BofAS Raises WUXI BIO's Target Price to HKD47 Following Strong Positive Earnings Announcement
Positive Profit Alert: WUXI BIO has issued a profit alert, projecting a 16.7% year-on-year revenue growth to RMB21.8 billion for 2025, which aligns with broker expectations due to new projects and expanded services.
Target Price Adjustment: BofA Securities has raised its target price for WUXI BIO from HKD41.8 to HKD47, maintaining a Neutral rating, while Nomura has also increased its target price to $50.54 following the preliminary 2025 results.
HSI Drops 242 Points at Midday, Driven by Technology Stocks; CN Developers and WUXI Series Surge
Market Performance: Hong Kong stocks faced a decline, with the HSI dropping 242 points (0.9%) to 27,023, while the HSCEI and HSTECH also fell by nearly 1% and 1.7%, respectively.
Tech Stocks Struggles: Major tech companies like NTES, BABA, and TENCENT saw significant drops in their share prices, with NTES down 3.8% and BABA down 2.1%, amid disappointing earnings reports and ongoing investment strategies.
Chinese Developers' Gains: Some Chinese developers, including CHINA VANKE and RONSHINECHINA, experienced gains due to reports of a potential RMB80 billion rescue package from the Shenzhen municipal government.
WUXI APPTEC's Success: WUXI APPTEC emerged as the best-performing blue chip, rising nearly 4% after Nomura raised its revenue expectations and target price, indicating strong future performance.
CANBRIDGE-B Rises Over 5% Following Announcement of 14.7% Discounted Share Placement to WUXI BIO Subsidiary
Share Placement Announcement: CANBRIDGE-B (01228.HK) has announced the placement of 84.0336 million shares, representing approximately 14.12% of its enlarged share capital, to WuXi Biologics HealthCare Venture at a price of HKD2.38 per share, which is a 14.7% discount to the previous closing price.
Fundraising Details: The total amount raised from this share placement is expected to be HKD200 million, with net proceeds estimated at around HKD199 million.
JPM Increases WUXI BIO (02269.HK) Price Target to $51 Following Positive Profit Alert and Robust Order Growth
WUXI BIO Financial Performance: WUXI BIO's pre-announced 2025 results exceeded market expectations, with projected full-year revenue of RMB21.8 billion, a 16.7% increase YoY, and a net profit of RMB4.9 billion, surpassing both market consensus and JPMorgan's forecasts.
JPMorgan's Revised Forecasts: JPMorgan raised its sales forecasts for WUXI BIO by 2-5% for 2025-2027 and 6-9% for 2028 and beyond, anticipating sales growth of 17.3% in 2026 and 18.0% in 2027.
Target Price Adjustment: Following the positive outlook, JPMorgan increased its target price for WUXI BIO from $37 to $51 and extended the target price deadline to December 2026, maintaining an Overweight rating.
Market Activity: WUXI BIO's stock experienced a decline of 3.096%, with significant short selling activity amounting to $316.79 million and a short selling ratio of 10.140%.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
HKD1.4 Billion Net Inflow from Southbound Trading into TENCENT
Southbound Trading Inflows: TENCENT (00700.HK) saw a significant net inflow of HKD1.4 billion, while MEITUAN-W (03690.HK) also had a notable inflow of HKD314.6 million in Southbound Trading.
Southbound Trading Outflows: POP MART (09992.HK) experienced a net outflow of HKD301.1 million, with ZIJIN MINING (02899.HK) and WUXI BIO (02269.HK) also recording substantial outflows.
Short Selling Activity: TENCENT had short selling of $1.61 billion with a ratio of 7.556%, while MEITUAN-W faced $1.88 billion in short selling at a ratio of 24.332%.
Market Overview: Overall, Southbound Trading net outflow totaled HKD0, accounting for 39.70% of the total transaction amount of HKD94.78 billion.
BofAS Raises WUXI BIO's Target Price to HKD47 Following Strong Positive Earnings Announcement
Positive Profit Alert: WUXI BIO has issued a profit alert, projecting a 16.7% year-on-year revenue growth to RMB21.8 billion for 2025, which aligns with broker expectations due to new projects and expanded services.
Target Price Adjustment: BofA Securities has raised its target price for WUXI BIO from HKD41.8 to HKD47, maintaining a Neutral rating, while Nomura has also increased its target price to $50.54 following the preliminary 2025 results.
HSI Drops 242 Points at Midday, Driven by Technology Stocks; CN Developers and WUXI Series Surge
Market Performance: Hong Kong stocks faced a decline, with the HSI dropping 242 points (0.9%) to 27,023, while the HSCEI and HSTECH also fell by nearly 1% and 1.7%, respectively.
Tech Stocks Struggles: Major tech companies like NTES, BABA, and TENCENT saw significant drops in their share prices, with NTES down 3.8% and BABA down 2.1%, amid disappointing earnings reports and ongoing investment strategies.
Chinese Developers' Gains: Some Chinese developers, including CHINA VANKE and RONSHINECHINA, experienced gains due to reports of a potential RMB80 billion rescue package from the Shenzhen municipal government.
WUXI APPTEC's Success: WUXI APPTEC emerged as the best-performing blue chip, rising nearly 4% after Nomura raised its revenue expectations and target price, indicating strong future performance.
